DIVI'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,951 INR | -0.35% |
|
+2.79% | +1.21% |
| 04-26 | Weak March Quarter Earnings Weigh Down Indian Equities on Friday | MT |
| 04-25 | Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity | MT |
ETFs positioned on Divi's Laboratories Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.68% | 6 M€ | +6.07% | - | |
| 0.20% | 11 M€ | +4.66% | ||
| 0.09% | 18 M€ | +6.09% | ||
| 0.08% | 2,808 M€ | +8.23% | - | |
| 0.08% | 441 M€ | +6.14% | - | |
| 0.08% | 149 M€ | +3.96% | - | |
| 0.07% | 4 M€ | -4.41% | - | |
| 0.06% | 117 M€ | +2.04% | - | |
| 0.03% | 31 M€ | +4.25% | - | |
| 0.03% | 7 M€ | +2.57% | - | |
| 0.02% | 7 M€ | +22.99% | - | |
| 0.01% | 15 M€ | +12.19% | ||
| 0.01% | 34 M€ | +2.62% | - | |
| 0.01% | 34 M€ | +6.21% | - | |
| 0.01% | 389 M€ | +7.11% | - | |
| 0.01% | 16 M€ | -4.51% | ||
| 0.00% | 39 M€ | +3.82% | - | |
| 0.00% | 302 M€ | +4.66% | - |
Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%).
At the end of March 2020, the group has 2 production sites located in India.
Sector
Pharmaceuticals
Calendar
26/05/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
3,951
INR
Average target price
3,442
INR
Spread / Average Target
-12.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.21% | 12.61B | |
| +26.54% | 681B | |
| +21.85% | 556B | |
| -4.86% | 361B | |
| +17.22% | 325B | |
| +5.36% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -4.08% | 157B |
- Stock Market
- Equities
- DIVISLAB Stock
- Funds and ETFs Divi's Laboratories Limited
